US Biosimilar Landscape: Multi-Stakeholder Analysis

Key Findings of a ZS-Sponsored Market Research Study

> Download

While there are a number of FDA-approved biosimilars so far, only a few have launched in the U.S. Over the next five years, some of the world’s best-known biologics may lose patent protection, opening the market to more biosimilars.

In a newly released report, ZS conducted a targeted survey with key U.S. decision-makers on trends and future expectations for the biosimilar landscape. To get maximum impact, the study targeted key decision makers across several organization types (IDN, PBM, MCO, GPO).

Download the report for the research findings and answers around few burning questions in the biosimilar space.